Combined treatment with JAK inhibitors and excimer laser may be superior to treatment with tacrolimus and laser therapy in pediatric vitiligo.

Phase 2/3 trial data show VDPHL01, an oral non-hormonal extended-release minoxidil, improves hair growth and patient-reported outcomes in male pattern hair loss.

The Centers for Medicare and Medicaid extended the Bridge program, which makes GLP-1s for obesity available for $50, through the end of 2027.

The FDA has approved Saphnelo (anifrolumab-fnia) for subcutaneous administration in patients with systemic lupus ...

Topical corticosteroids with FxCO2 in patients with VLSC was associated with significant pruritus improvement and patient satisfaction.

Pregnancy and the postpartum period among patients with HS is associated with an increased risk for several maternal and ...

Stephen Sayle worked for Fontem Ventures, a tobacco company subsidiary, before becoming the CDC’s deputy director for legislative affairs.

Intralesional nivolumab appeared effective for treating precancerous oral lesions in a phase 1, open-label, dose-escalation trial.

A district judge declined the Louisiana attorney general's request to pause FDA rules that allow mifepristone to be ordered ...

FDA expands Dupixent approval for children aged 2 to 11 years with chronic spontaneous urticaria symptomatic despite H1 antihistamine use.

The expanding armamentarium of biologic therapies for patients with atopic dermatitis (AD) allows flexibility in treatment strategies for adolescents and adults. Current evidence indicates that ...